Coronary heart disease in Diabetics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 25: | Line 25: | ||
==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663 }} </ref>== | ==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663 }} </ref>== | ||
===Recommendations for diagnosing diabetes<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663 }} </ref>=== | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Screening for diabetes is recommended in all individuals with CVD, using fasting glucose and/or HbA1C<ref name="pmid33298413">{{cite journal| author=American Diabetes Association| title=2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. | journal=Diabetes Care | year= 2021 | volume= 44 | issue= Suppl 1 | pages= S15-S33 | pmid=33298413 | doi=10.2337/dc21-S002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33298413 }} </ref><ref name="pmid20978099">{{cite journal| author=Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K | display-authors=etal| title=Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. | journal=Diabetes Care | year= 2011 | volume= 34 | issue= 1 | pages= 145-50 | pmid=20978099 | doi=10.2337/dc10-1206 | pmc=3005450 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20978099 }} </ref><ref name="pmid27216887">{{cite journal| author=Sattar N, Preiss D| title=Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure. | journal=Lancet Diabetes Endocrinol | year= 2016 | volume= 4 | issue= 7 | pages= 555-6 | pmid=27216887 | doi=10.1016/S2213-8587(16)30097-3 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27216887 }} </ref><ref name="pmid35022686">{{cite journal| author=Mak KH, Vidal-Petiot E, Young R, Sorbets E, Greenlaw N, Ford I | display-authors=etal| title=Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. | journal=Eur J Prev Cardiol | year= 2022 | volume= 28 | issue= 16 | pages= 1795-1806 | pmid=35022686 | doi=10.1093/eurjpc/zwab011 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35022686 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}}{{WS}} | {{WH}}{{WS}} | ||
Revision as of 06:34, 21 December 2023
|
2016 ADA Guideline Recommendations |
|
Types of Diabetes Mellitus |
|---|
|
2016 ADA Standard of Medical Care Guideline Recommendations |
|
Cardiovascular Disease and Risk Management |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]; Seyedmahdi Pahlavani, M.D. [3]; Tarek Nafee, M.D. [4]
2016 ADA Standards of Medical Care in Diabetes Guidelines[1]
Screening
| "1.In asymptomatic patients, routine screening for coronary artery disease is not recommended as it does not improve outcomes as long as atherosclerotic cardiovascular disease risk factors are treated (Level of Evidence: A)" |
| "2. Consider investigations for coronary artery disease in the presence of any of the following: atypical cardiac symptoms (e.g., unexplained dyspnea, chest discomfort); signs or symptoms of associated vascular disease including carotid bruits, transient ischemic attack, stroke, claudication, or peripheral arterial disease; or electrocardiogram abnormalities (e.g., Q waves) (Level of Evidence: E)" |
Treatment
| "1.In patients with known atherosclerotic cardiovascular disease, use aspirin and statin therapy (if not contraindicated) "(Level of Evidence: A)" and consider ACE inhibitor therapy. (Level of Evidence: C) to reduce the risk of cardiovascular events." |
| "2.In patients with prior myocardial infarction, b-blockers should be continued for at least 2 years after the event (Level of Evidence: B)" |
| "3.In patients with symptomatic heart failure, thiazolidinedione treatment should not be used (Level of Evidence: A)" |
| "4.In patients with type 2 diabetes with stable congestive heart failure, metformin may be used if renal function is normal but should be avoided in unstable or hospitalized patients with congestive heart failure (Level of Evidence: B)" |